Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).
A Prospective, Non-Randomized, Multi-Center, Two-Arm Study Evaluating the Serene Sleep Palatal Implant System
This clinical investigation is a prospective, non-randomized, parallel-group clinical investigation conducted at two (2) investigative sites. Study participants will be assigned to one of two study groups, snoring and obstructive sleep apnea, in a parallel manner based on predefined eligibility criteria.
The study aims to evaluate and compare outcomes between the two groups under investigation. The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
The design allows for the concurrent enrollment and follow-up of participants in both arms, enabling direct observation of differences in safety across the groups over time.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Chief Technology Officer
- 電話番号:415-707-1107
- メール:kelsey@serenesleep.com
研究場所
-
-
California
-
San Francisco、California、アメリカ、94102
- Aesthetic Surgery Center
-
コンタクト:
- Michael R Macdonald, MD
- 電話番号:415-956-3223
- メール:Contactus@drMMacdonald.com
-
主任研究者:
- Michael R Macdonald, MD
-
-
Georgia
-
Evans、Georgia、アメリカ、30907
- Augusta ENT
-
コンタクト:
- Jonathan P Lindman, MD
- 電話番号:706-868-5676
- メール:lindmanresearch@gmail.com
-
主任研究者:
- Jonathan P Lindman, MD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
INCLUSION CRITERIA
A potential participant must meet ALL the following criteria to be enrolled into this study:
- Participant is ≥18 years of age.
- Participant has Body Mass Index (BMI) less than or equal to 30 kg/m²
- Participant has a tonsil grade less than or equal to 2
- Participant has a Friedman Tongue Position (FTP) I or II
- Participant is able to provide voluntary written informed consent.
For a snoring participant to be selected for the study:
Confirmed identification of palatal snoring
- Investigators will utilize standard of care clinical assessment methods to confirm the presence of palatal snoring prior to enrollment. These methods may include patient-reported history, physical examination of the upper airway, and auscultation or audio recordings.
Confirmed elimination of potential sleep apnea diagnosis
- If the evaluating doctor suspects that the participant may be experiencing OSA, investigators will utilize standard of care clinical assessment methods to confirm OSA.
- A resulting AHI <5 would classify the participant as an eligible snoring subject
For an OSA participant to be selected for study:
Confirmed identification of apnea caused by palatal collapse
- Investigators should be able to make this identification through intraoral evaluation in accordance with their standard of care
Confirmed mild-to-moderate classification of OSA
- If the evaluating investigator knows or suspects that the participant may be experiencing OSA, standard of care diagnostic methods will be used as confirmation.
- A resulting AHI between 5 and 30 would classify the participant as an eligible OSA subject.
EXCLUSION CRITERIA
A potential participant will be excluded from enrollment if ANY of the following conditions apply:
- A record of allergic reaction to polyethylene terephthalate (PET) / polyester
- An overly sensitive gag reflex
- Septal deviation or nasal obstruction
- Nasal polyps
- Severe seasonal allergies
- Soft palate length insufficient to accommodate implants
- Prior Diagnosis of Lingual tonsil hypertrophy
- Hypopharyngeal obstruction
- Previous pharyngeal surgery
- Previous upper respiratory tract cancer or radiation therapy
- Active respiratory tract infection
- Dysphagia or speech disorder
- Neurologic disorder
- Unstable psychiatric disorder
- Pregnant or breastfeeding
- History of falling asleep driving or Motor Vehicle Accident (MVA) due to sleepiness
- Clinical Presentation that suggests Severe OSAHS (ESS >20, participant report of choking or gasping during sleep, etc.)
- Marfan's Syndrome, Ehler-Danlos syndromes or other disorders of connective tissue and/or muscular tissue
- Other sleep disorders
- Other significant craniofacial anomaly
Participant is participating in any of the following:
- A study with the same or similar primary endpoint
- Any study in which the investigator determines may interfere with the results of this study
- Participant is unwilling to complete all study related assessments and follow-up visits
- Participant is unwilling or unable to abstain from all alcohol consumption for 24 hours leading up to the intake sleep study
- Participant is unwilling or unable to abstain from all smoking, vaping, and/or oral tobacco products for 48 hours following the procedure
- Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Snoring Group
Implant with the Serene Sleep Palatal Implant System
|
Serene Sleep Palatal Implant System
|
|
実験的:Mild to Moderate OSA Group
Implant with the Serene Sleep Palatal Implant System
|
Serene Sleep Palatal Implant System
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants with Implant Extrusion at 30 Days and Absence of Serious Adverse Device Effects (SADEs) [Hybrid Composite Safety Endpoint]
時間枠:From baseline to 30 days post-procedure
|
The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
|
From baseline to 30 days post-procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change is Visual Analogue Scale (VAS) Score
時間枠:From baseline to 30 days post-procedure
|
The change in subjective snoring severity as measured by a 10 cm Visual Analogue Scale (VAS), scored 0-10, where 0 = no snoring and 10 = extremely annoying snoring (higher scores indicate worse outcome).
|
From baseline to 30 days post-procedure
|
|
Change in Snoring Outcomes Survey (SOS)
時間枠:From baseline to 30 days post-procedure
|
The change in subjective snoring as measured by the Snoring Outcomes Survey (SOS), an 8-item validated instrument assessing intensity, duration, frequency, and impact of snoring/sleep-disordered breathing symptoms.
|
From baseline to 30 days post-procedure
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in daytime Epworth Sleepiness Scale (ESS)
時間枠:From baseline to 30 days post-procedure
|
The change in daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), a validated 8-item questionnaire scored 0-24, where 0 = no daytime sleepiness and 24 = severe daytime sleepiness (higher scores indicate worse outcome).
|
From baseline to 30 days post-procedure
|
|
Change in Apnea-Hypopnea Index (bAHI3) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
AHI Score calculated using a 3% oxygen desaturation threshold (bAHI3), collected via the Belun Sleep System HSAT device.
Data will be anonymized; complete reports will be utilized as exploratory data.
|
From baseline to 30 days post-procedure
|
|
Change in Apnea-Hypopnea Index (bAHI4) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
AHI Score calculated using a 4% oxygen desaturation threshold (bAHI4), collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Minimum Oxygen Saturation (SpO₂) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
Minimum SpO₂ recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Time with Oxygen Saturation ≤90% via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
Total cumulative duration during which SpO₂ was recorded at or below 90%, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Sleep Efficiency via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
Sleep efficiency calculated as the proportion of time in bed spent asleep, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Total Sleep Time (TST) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
Total duration of sleep recorded during the study period, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Mean Pulse Rate via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
Mean pulse rate recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Arrhythmia Ratio via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
|
Ratio of arrhythmic heartbeats to total heartbeats recorded during the sleep study period, collected via the Belun Sleep System HSAT device
|
From baseline to 30 days post-procedure
|
|
Change in Auditory Evaluation of Snoring
時間枠:From baseline to 30 days post-procedure
|
Outcome 6a: "Change in Objective Snoring Volume (decibels) via Audio Recording" - the change in mean snoring volume (dB) captured by at-home overnight audio recording. Outcome 6b: "Change in Objective Snoring Frequency (Hz) via Audio Recording" - the change in dominant snoring frequency captured by at-home overnight audio recording. |
From baseline to 30 days post-procedure
|
|
Proportion of Participants with Implant Migration or Trend Toward Extrusion as Assessed by Oropharyngeal Examination at 30 Days
時間枠:Date of procedure to 30 days post-implant
|
At each post-procedure visit (Day 7 and Day 30), the physician will conduct a standardized oropharyngeal examination to evaluate and document whether implant location has changed from the original placement position or is trending toward extrusion.
Findings will be recorded as a binary outcome (yes/no change in location) and summarized descriptively.
|
Date of procedure to 30 days post-implant
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- TESTING-055
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Palatal Implant Systemの臨床試験
-
Polares Medical SAPolares Medical, Inc.まだ募集していません
-
Polares Medical SAPolares Medical, Inc.まだ募集していません
-
University of Turin, Italy完了
-
Abbott Medical Devices完了
-
Seoul National University HospitalHansBiomed Co.,Ltd.積極的、募集していない
-
Reciprocal LabsCalifornia HealthCare Foundation完了